23 results
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
duration same as for treatment ... Note: Treatment ... #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology
CNS Manifestations of Systemic Lupus Erythematosus (SLE)

Clinical Manifestations: Demyelinating Syndrome, Headache, Movement disorders, Seizure disorders, Aseptic
Systemic Lupus Erythematosus ... Cerebrovascular Disease ... Puncture, EEG Treatment ... APS), Secondary prevention ... CNS #neurology #rheumatology
Behcet's Syndrome - Treatment
Ulcers:
 • Treatment: Topical steroids
 • Prevention: Colchicine
 • Azathioprine for refractory disease
Arthritis:
Behcet's Syndrome - Treatment ... Ulcers: • Treatment ... Topical steroids • Prevention ... #management #pharmacology ... #rheumatology
Drugs Used for the Treatment of COVID-19 Infection

** Editor Note (from ophthalmology MD input) - Hydroxychloroquine/chloroquine
Drugs Used for the Treatment ... of COVID-19 Infection ... Even with macular disease ... #COVID19 #Pharmacology ... #Table #Management
IDSA Recommendations for Treating Cytomegalovirus Infections in HIV-AIDS
Preventing CMV Disease:
 • CMV end-organ disease is best
Cytomegalovirus Infections ... in HIV-AIDS Preventing ... CMV Disease: ... CMV end-organ disease ... #HIVAIDS #pharmacology
Macrophage Activation Syndrome (MAS)
Classified among the secondary or acquired forms of haemophagocytic lymphohistiocytosis (sHLH)

What?
A subset of
Systemic lupus erythematosus ... systemic lupus erythematosus ... SLE], AOSD) • Infection ... Treatment: • Corticosteroids ... #Rheumatology
Summary of actions of some Cholinergic Agonists

Bethanechol 
• Used in treatment of urinary retention 
• Binds
of urinary retention ... for Alzheimer's disease ... moderate to severe disease ... Cholinergic #Agonists #Pharmacology ... #Table #Summary
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
mucoadhesive buccal tablet ... chew, or crush tablet ... mucosal #IDSA #Prevention ... opportunistic #infections ... #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Varicella Zoster Virus (VZV) Infections in HIV-AIDS
Pre-Exposure Prevention of VZV
Recommendations for Preventing ... Pre-Exposure Prevention ... confirmation of disease ... vaccination results in disease ... #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating HHV-8 Diseases—Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL), Multicentric Castleman’s
Recommendations for Preventing ... recommended for KS treatment ... #Treatment #management ... opportunistic #infections ... #HIVAIDS #pharmacology